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Abstract: It is well established that disruption of apoptosis may lead to tumor initiation, progression or metastasis. It is also
well documented that many anticancer drugs induce apoptosis. In the earlier studies, the dopamine D2 receptor agonist
bromocriptine (BC) and somatostatin analog octreotide (OCT) were found to inhibit the growth of the estrogen-induced rat
prolactinoma. Our previous investigations, applying the TUNEL method showed the involvement of the pro-apoptotic effect
in the action of BC, and to a lesser degree, in the action of OCT. The aim of the present study was to investigate whether the
pro-apoptotic action of these drugs involves the increased expression of Bax - a member of Bcl-2 protein family which is
known to play an important role in the regulation of apoptosis. Male four-week Fisher 344 rats were used in the experiment.
Capsules containing diethylstilboestrol (DES) were implanted subcutaneously. Six weeks after the implantation the rats were
given OCT (2 × 25 µg/animal/24), BC (3 mg/kg b.w./24 h) or OCT and BC at the above doses for 10 days. Bax expression
was detected by immunohistochemistry. Prolactin (PRL) in blood serum was measured by radioimmunoassay (RIA). It has
been found that both OCT and BC, alone or in combination, significantly reduce the tumor weight. Both OCT and BC
suppressed PRL levels, but the inhibitory effect of BC was stronger than that of OCT. It has been found that the treatment with
OCT and BC, alone or in combination, causes a significant increase in Bax expression in the rat prolactinoma cells. Our findings
indicate that anti-tumoral action of bromocriptine and to some extent the action of octreotide in the experimental rat
prolactinoma is connected with the induction of apoptosis and is associated with increased Bax expression.
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Introduction
The cell death may be the result of either necrosis or
apoptosis. In contrast to necrosis, apoptosis is a com-
plex, gene-directed process whereby individual cells are
triggered to undergo self-destruction. The major bio-
chemical event considered as a hallmark of apoptosis is
the cleavage of DNA into oligonucleosomal (180-200-
bp) fragments (for review see [12, 21, 23]).
The Bcl-2 (B cell leukemia/lymphoma-2) family
of proteins plays an important role in the regulation
of apoptosis (for review see [1, 8, 20]). It includes
both the death-promoting as well as the death-inhi-
biting members. One of the death-promoting pro-
teins is Bax.
The studies concerning apoptosis in the pituitary
gland show that the apoptotic index in both nontumorous
and adenomatous pituitary is low [7, 14, 17]. Bromocrip-
tine - D2 dopamine receptor agonist, has been shown to
induce apoptosis in pituitary tumors in vivo [5, 36] and
in vitro [11, 31, 33, 34, 35]. However, other studies
provide contradictory results [13, 14, 25]. The data
concerning apoptosis in pituitary tumors after somatos-
tatin analog treatment are also controversial. The induc-
tion of apoptosis has been reported only in a few studies
in vivo [30] and in vitro [24]. However, the other studies
have not revealed apoptosis in pituitary tumors after
somatostatin analog therapy either in vivo [18, 22] or in
vitro [4].
In our previous paper, we examined the effects of D2
dopamine receptor agonist bromocriptine and somatos-
tatin analog octreotide on apoptosis (visualized by the
TUNEL method) in the rat prolactin-secreting pituitary
tumor [9]. We found that both bromocriptine and octre-
otide enhanced the number of apoptotic cells in the
tumor, but the pro-apoptotic effect of bromocriptine was
more pronounced. Unexpectedly, the joint effect of oc-
treotide and bromocriptine was much lower than that of
bromocriptine alone.
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In the present study we investigate whether the pro-
apoptotic action of these drugs involves the increased
expression of the pro-apoptotic Bax protein.
Materials and methods
Four week old male Fischer 344 rats weighing 50-70 g, maintained
in controlled illumination regime (12L/12D), with free access to
standard laboratory food and tap water, were used in the experiment.
Capsules containing 8-10 mg of diethylstilboestrol (DES, Sigma)
each were implanted subcutaneously (s.c.) in the lumbar region. Such
capsules were estimated to release 18-45 µg of DES daily [32].
Six weeks after the implantation of capsules the rats were divided
into 5 groups and treated with the following substances for 10 days:
Group IA - control: 0.25 ml of physiological saline s.c., once daily;
Group IB - control: 0.25 ml of 50% ethanol in physiological saline
s.c., twice daily; Group II: octreotide (OCT, Sandostatin, Novartis)
at a dose of 25 µg/animal s.c., twice daily; Group III: bromocriptine
(BC, Bromocriptine mesylate, Lek) at a dose of 3 mg/kg b.w. s.c.,
once daily; Group IV: OCT + BC at the above doses. BC was
dissolved in 50% ethanol in physiological saline.
On the eleventh day the animals were sacrificed. Blood and
pituitaries were collected. The glands were weighed, fixed in 4%
formalin in phosphate buffered saline and then embedded in paraffin
wax. The experimental protocol was approved by the Local Ethical
Committee for Animal Experimentation (decision Nr Ł/BD/61, 11
June 2001).
Bax expression was detected by immunohistochemistry using
commercial monoclonal antibodies (Polyclonal rabbit anti-
mouse/rat Bax antibody, Pharmingen, Becton Dickinson Company,
San Diego, CA 92121, USA) and DAKO EnVisionTM+ System,
HRP/DAB (rabbit ready-to-use detection system using the labelled
polymer method, DAKO Corporation, Carpimena, CA 93013, USA)
- a kit containing three bottles. The paraffin sections were dewaxed
and subjected to microwave antigen retrieval in 10 mM citrate buffer
(pH 6.0) for 5 min twice. Endogenous peroxidase was blocked with
3% hydrogen peroxide for 15 min. The sections were then preblocked
with 5% normal sheep serum for 30 min and incubated with anti-Bax
antibody (1:2000) for 2 h at a room temperature. Sections were then
washed and incubated with secondary antibody for 30 min. The
reaction product was visualized by diaminobenzidine tetrachydro-
chloride after 4 min of incubation. Finally, the sections were counter-
stained with haematoxylin. Negative control was performed by
omitting anti-Bax antibodies. Mice thymus was used as a positive
control.
Bax expression was evaluated by counting at random 3000 cells
from each section at × 600 magnification. The number of Bax-im-
munopositive cells per 1000 was assessed in each section. Only the
cells exhibiting a strong, specific cytoplasmic staining were counted.
The 0.5 mm boundary around the section was excluded from analysis
to circumvent artifactual staining which may occur at the edges of
tissue sections.
Prolactin (PRL) was assayed in blood serum using the rat prolac-
tin 125I assay system with magnetic separation (Amersham, UK) and
expressed in ng/ml. The method sensitivity is ~0.7 ng/tube (7.0
ng/ml).
Statistical analysis was performed using ANOVA followed by
LSD test. P<0.05 was considered as the borderline of statistic signi-
ficance. As there was no statistically significant difference between
both control groups, they were pooled.
Results
Six weeks after the implantation of DES, the animals of
the control group exhibited the tumorous enlargement of
the anterior pituitary. The data concerning the tumor
weight are shown in Figure 1. It was found that both
OCT and BC, alone or in combination, significantly
reduced the tumor weight. 
The animals implanted with DES had very high PRL
levels. All treatment options resulted in a statistically
Fig. 3. Effects of octreotide (OCT) and bromocriptine (BC) on Bax
expression in rat estrogen-induced prolactinoma cells. *p<0.05 vs K
(control), **p<0.05 vs BC.
Fig. 1. Effects of octreotide (OCT) and bromocriptine (BC) on tumor
weight in rat estrogen-induced prolactinoma. *p<0.05 vs K (control).
Fig. 2. Effects of octreotide (OCT) and bromocriptine (BC) on serum
prolactin (PRL) level in rat estrogen-induced prolactinoma. *p<0.05
vs K (control), **p<0.05 vs OCT.
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significant reduction of PRL serum level (Fig. 2). The
effect of BC was stronger than that of OCT. The joint
action of OCT and BC caused a more pronounced de-
crease of PRL level as compared to OCT alone.
The treatment with both OCT and BC, alone or in
combination, caused a significant (approx. tenfold) in-
crease in Bax expression in the rat prolactinoma cells.
The joint effect of OCT and BC was stronger than that
of BC alone (Figs. 3, 4).
Discussion
In the only previous study concerning Bax expression in
pituitary tumors, Bax was demonstrated using immu-
nohistochemistry to be moderately expressed in normal
human pituitary and in all examined human pituitary
adenomas, from patients with or without a preoperative
treatment either with octreotide or with dopamine agon-
ists [14]. Bax expression was decreased in pituitary
carcinomas. Bcl-X and Bad, two other pro-apoptotic
proteins and Bcl-2, exhibiting anti-apoptotic properties,
were expressed at a similar level to Bax. Bcl-2 was
expressed in ~70% of pituitary adenomas. 
Bcl-2 expression in human pituitary tumors was also
investigated by Wang et al. [29], who detected Bcl-2
immunoreactivity in 30% of tumors and in none of
normal pituitaries. Turner et al. [27] examined 160
human pituitary adenomas and found Bcl-2 expression
Fig. 4. Immunostaining for Bax in rat
estrogen-induced prolactinoma in
untreated rats (a) and after octreotide
(b), bromocriptine (c) and combined
treatment with both drugs (d). A: ×
400, B-D: × 200.
Octreotide, bromocriptine and Bax expression in prolactinoma           37
in over 50% tumors including over 70% prolactinomas.
Higher Bcl-2 expression was found in the more vascular
tumors. Unfortunately, in both studies cited above no
data concerning previous pharmacotherapy of the pitui-
tary tumors are shown. 
In vitro studies concerning two pituitary adenoma
cell lines (GH3 and AtT-20) revealed a decreased ex-
pression of Bcl-2 and an accumulation of the wild-type
p53 associated with bromocriptine-induced apoptosis
[35]. It has been also found that the cell remodeling of
the anterior pituitary after the termination of lactation
occurs through the process of apoptosis and involves an
increase in Bax and a decrease in Bcl-2 expression [2].
In the present study we demonstrate an increased
expression of Bax in a rat prolactin-secreting pituitary
tumor after bromocriptine and octreotide treatment, as
compared with the untreated tumors. In the light of
earlier immunohistochemical investigations [15] which
revealed that DES-induced rat pituitary tumors con-
tained almost solely lactotrophs, it can be assumed that
the increased Bax expression concerns lactotrophs. In
our previous study [9] concerning the same experimen-
tal model we demonstrated using the TUNEL method
that the antitumoral action of bromocriptine and to some
extent the action of octreotide, was connected with the
induction of apoptosis. The joint administration of oc-
treotide and bromocriptine resulted unexpectedly in the
attenuation of the pro-apoptotic effects of the latter. The
attenuation of the pro-apoptotic action of bromocriptine
by octreotide may be the result of the cytoprotective
effect of somatostatin analogs. Cytoprotection is an
organ-specific reduction or prevention of vulnerability
of cells and tissues against injury [28]. Cytoprotective
properties of somatostatin and its analogs have been
demonstrated in several experimental models, espe-
cially in the gastrointestinal tract [16, 19, 26]. It has also
been found that cytoprotective effects of somatostatin
can be dissociated from its endocrine effects, suggesting
that different mechanisms are involved in cytoprotection
and secretory cell inhibition [28]. Cytoprotective action
of somatostatin and its analogs has not yet been investi-
gated in the pituitary. The hypothesis presented above
needs to be verified.
In the present study, similar intensity of Bax immu-
nostaining was observed after bromocriptine and octre-
otide, administered separately or in combination. A
question arises how this discrepancy could be explained.
It should be stressed that the TUNEL method is based
on the detection of oligonucleosomal DNA fragments
which are characteristic of cells in the later stage of the
apoptotic process [6]. It is possible that high suscepti-
bility to apoptosis evidenced by Bax expression does not
necessarily commit all Bax-immunopositive cells to the
apoptotic cell death.
In conclusion, our results suggest that anti-tumoral
action of bromocriptine and to some extent the action of
octreotide in the experimental rat prolactinoma is con-
nected with the induction of apoptosis and associated
with increased Bax expression.
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